Results 161 to 170 of about 3,858,904 (290)

Non-Linear Mixed Models for the Characterization of Growth Trajectory Measured by Ultrasound of 'San Pedreño' Creole Pig Breed From Colombia. [PDF]

Vet Med Sci
Salamanca-Carreño A, Parés-Casanova PM, Rangel-Pachón DE, Valverde A, Toalombo-Vargas PA, Vélez-Terranova M.   +5 more
europepmc   +1 more source

nlive: an R package to facilitate the application of the sigmoidal and random changepoint mixed models. [PDF]

BMC Med Res Methodol, 2023
Capuano AW, Wagner M.
europepmc   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Multi-response phylogenetic mixed models: concepts and application. [PDF]

Biol Rev Camb Philos Soc
Halliwell B, Holland BR, Yates LA.
europepmc   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

When the outcome is compositional: A method for conducting compositional response linear mixed models for physical activity, sedentary behaviour and sleep research. [PDF]

PLoS One
Miatke A, Stanford T, Olds T, Fraysse F, Maher C, Martin-Fernandez JA, Dumuid D.   +6 more
europepmc   +1 more source

Bayes Factors for Mixed Models: Perspective on Responses. [PDF]

Comput Brain Behav, 2023
van Doorn J, Aust F, Haaf JM, Stefan AM, Wagenmakers EJ.   +4 more
europepmc   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

plmmr: an R package to fit penalized linear mixed models for genome-wide association data with complex correlation structure. [PDF]

Brief Bioinform
Peter TK, Reisetter AC, Lu Y, Rysavy OA, Breheny PJ.   +4 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source